Trial Profile
Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2014
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Otsuka Pharmaceutical Development & Commercialization
- 19 Apr 2014 New trial record